Skip to content
10-Q

Quarterly Report

vTv Therapeutics Inc. VTVT

0001641489-25-000060

← back to feed
Filed
Nov 6, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Operating Cash Flow Q3 2025 · Sep 30, 2025 −$16M
Operating Cash Flow Q3 2025 · Sep 30, 2024 −$20.48M
Cash And Equivalents Q3 2025 · Sep 30, 2025 $98.5M
Cash And Equivalents Q3 2025 · Dec 31, 2024 $36.75M
Stockholders Equity Q3 2025 · Sep 30, 2025 $70.54M
Stockholders Equity Q3 2025 · Dec 31, 2024 $12.2M
Current Liabilities Q3 2025 · Sep 30, 2025 $10.16M
Current Liabilities Q3 2025 · Dec 31, 2024 $5.2M
Total Liabilities Q3 2025 · Sep 30, 2025 $28.95M
Total Liabilities Q3 2025 · Dec 31, 2024 $23.97M
Current Assets Q3 2025 · Sep 30, 2025 $99.46M
Current Assets Q3 2025 · Dec 31, 2024 $38.11M
Total Assets Q3 2025 · Sep 30, 2025 $99.49M
Total Assets Q3 2025 · Dec 31, 2024 $38.27M
Sga Expense Q3 2025 · Sep 30, 2025 $3.68M
Sga Expense Q3 2025 · Sep 30, 2025 $10.97M
Sga Expense Q3 2025 · Sep 30, 2024 $3.28M
Sga Expense Q3 2025 · Sep 30, 2024 $10.98M
Rd Expense Q3 2025 · Sep 30, 2025 $7.02M
Rd Expense Q3 2025 · Sep 30, 2025 $13.95M
Rd Expense Q3 2025 · Sep 30, 2024 $3.22M
Rd Expense Q3 2025 · Sep 30, 2024 $9.31M
Net Income Q3 2025 · Sep 30, 2025 −$8.7M
Net Income Q3 2025 · Sep 30, 2025 −$19.84M
Net Income Q3 2025 · Sep 30, 2024 −$4.78M
Net Income Q3 2025 · Sep 30, 2024 −$14.83M
Operating Income Q3 2025 · Sep 30, 2025 −$10.7M
Operating Income Q3 2025 · Sep 30, 2025 −$24.92M
Operating Income Q3 2025 · Sep 30, 2024 −$6.51M
Operating Income Q3 2025 · Sep 30, 2024 −$19.29M
Revenue Q3 2025 · Sep 30, 2025 $0
Revenue Q3 2025 · Sep 30, 2025 $0
Revenue Q3 2025 · Sep 30, 2024 $0
Revenue Q3 2025 · Sep 30, 2024 $1M